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Abstract
Background: Drug resistance in bacterial pathogens is an increasing problem, which stimulates research. However,
our understanding of drug resistance mechanisms remains incomplete. Fortunately, the fast-growing number of
fully sequenced bacterial strains now enables us to develop new methods to identify mutations associated with
drug resistance.
Results: We present a new comparative approach to identify genes and mutations that are likely to be associated
with drug resistance mechanisms. In order to test the approach, we collected genotype and phenotype data of
100 fully sequenced strains of S. aureus and 10 commonly used drugs. Then, applying the method, we re-
discovered the most common genetic determinants of drug resistance and identified some novel putative
associations.
Conclusions: Firstly, the collected data may help other researchers to develop and verify similar techniques.
Secondly, the proposed method is successful in identifying drug resistance determinants. Thirdly, the in-silico
identified genetic mutations, which are putatively involved in drug resistance mechanisms, may increase our
understanding of the drug resistance mechanisms.
Introduction
The problem of bacterial drug resistance did not exist in
1930s, when antibiotics were introduced to treat bacterial
infections. Since then, due to various factors–such as
irresponsible dosage of antibiotics, naturally occurring
mutations, transmission of drug-resistant strains, etc.–
drug resistance has become a serious health problem.
This has drawn the attention of WHO (World Health
Organization), ECDC (European Centre for Disease Pre-
vention and Control) and CDC (Centers for Disease Con-
trol and Prevention), which monitor and report the
spreading of drug-resistant pathogens in the world. As a
consequence, for example, WHO launched in 2006 a new
global program “Stop TB Strategy” to fight the spreading
of M. tuberculosis (MTB). A recent WHO report on
MTB estimates that the bacteria was responsible for
around 1.7 million deaths world-wide in 2009 [1].
According to the report, 3.3% of new MTB cases in 2009
were multi-drug resistant (MDR). Moreover, 58 countries
reported cases of extensively-drug-resistant (XDR) iso-
lates of the bacteria. Very recently, ECDC reported that
as high as 58% of all Staphylococcus aureus isolates tested
in Malta was methicillin resistant (MRSA) [2].
The emergence of drug resistance is appalling, because it
is often not economically justifiable for pharmaceutical
companies to develop new drugs against it [3]. One pro-
mising approach to address the problem is to use old
drugs that were designed for treating other diseases and
are also effective against pathogens [4]. An effort in this
direction was recently undertaken in a research study on
M. tuberculosis [5]. The authors used three-dimensional
docking to identify in-silico some putative drug-target
interactions. For example, they predicted Comtan, a drug
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used in treating Parkinson’s disease, as potentially effective
against M. tuberculosis infections.
The need of more efficient strategies to develop new
drugs stimulates research to better understand drug
resistance mechanisms. Several drug resistance mechan-
isms have been discovered so far. They can be categor-
ized as: (i) drug target modification; (ii) drug molecule
modification by specialized enzymes; (iii) reduced accu-
mulation of the drug inside a bacteria cell by decreased
cell wall permeability or by pumping out the drug; and
(iv) alternative metabolic pathways [6]. Moreover, there
are known genes and mutations responsible for most of
the drug resistance mechanisms. While genomics can be
used on samples before and after drug resistance
emerges to identify the likely associated mutations, most
of the known mutations and genes associated with drug
resistance were discovered by analyzing a priori candi-
dates such as drug target genes or genes located on
plasmids. Some information on drug target genes is
available in the drugbank.ca database [7]; and some lists
of genes known to be responsible for drug resistance
(specific to bacterial species and drugs) are available in
the ARDB (Antibiotic Resistance Genes Database) data-
base [8].
Despite the above mentioned achievements, our under-
standing of drug resistance mechanisms is still incomplete.
For example, there are reports of S. aureus isolates with
atypical drug resistance profiles [9-11], which have not
been explained yet. We hypothesize that these atypical
drug resistance profiles might be due to genomic muta-
tions in genes which are not a priori suspected of being
involved in drug resistance mechanisms.
In this work, we use whole-genome sequences to iden-
tify and associate genetic mutations with drug resistance
phenotype for bacterial strains (within S. aureus). Thus,
conceptually our approach is similar to Genome-Wide
Association Study (GWAS) approaches, which have been
successfully applied to identify SNPs associated with
human diseases [12,13]. We hypothesize that similar
approaches, when applied to bacteria, should bring inter-
esting results. However, it may not make sense to directly
transfer this methodology to bacteria, because, for exam-
ple, horizontal gene transfer (HGT) plays an important
role in the evolution of bacteria. Besides mutations which
would explain the reported atypical drug resistance pro-
files, we expect, by applying our approach, to identify
also mutations that can be interpreted as compensatory
mutations. These compensatory mutations are not
directly involved in drug resistance, but they are impor-
tant to neutralizing the deleterious effect (caused by
mutations directly responsible for the resistance mechan-
isms) on bacterial fitness [14-16].
There are published studies, based on comparative
analysis of whole-genome sequences, associating genetic
mutations with drug resistance [17-21]. However, the
methodologies used in these studies are simple and
were applied to a relatively small number of strains. In
our opinion, this is caused by two main problems: first,
the number of fully sequenced bacterial strains within
the same species have not been sufficiently large until
recently; second, phenotype data with respect to drug
susceptibility tests are spread throughout the literature
and are not easy to collect.
In this work, we collected genotype data for 100 fully
sequenced S. aureus strains and addressed the second
problem by a careful search of the literature for results
of drug susceptibility tests of the strains considered. We
also developed and tested a new approach to associate
mutations and genes with drug resistance.
Materials and methods
Below we present details of our methodology including
the problem setting, collection of data and subsequent
steps of the identification of drug resistance associated
genetic features. These subsequent steps comprise:
• unification of protein-coding gene annotations of
bacterial strains and determination of gene families;
• computing multiple alignments for the gene
families and reconstructing the consensus phyloge-
netic tree;
• identification of genetic features, possibly asso-
ciated with drug resistance, such as point mutations
and gene gain/losses, based on the multiple align-
ments and the determined gene families; and
• association of genetic features with drug resistance
phenotypes.
Problem setting
We consider a set S of bacterial strains and their
response to the application of a given drug. The response,
which we called drug resistance profile, is represented by
a vector v : S → {′S′,′ R′,′ ?′} , where by ‘S’ and ‘R’ we
denote respectively drug-susceptible and drug-resistant
strain phenotypes, by ‘?’ we indicate that the phenotype is
unknown. Additionally, we denote by SSv and SRv the
sets of drug-susceptible and drug-resistant strains for a
given drug resistance profile, respectively.
We also assume to have a given set of genetic muta-
tions among the considered bacterial strains. Analogous
to drug resistance profiles, we represent mutations as
vectors m : S →
∑
∪ {′?′} , where ∑ denotes an alpha-
bet of possible states, such as amino acids in the strain
sequence corresponding to a given position in the multi-
ple alignment. By ‘?’ in the mutation profile we denote
strains which are not present in the aligned gene family
corresponding to the considered point mutation.
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Then, the problem is mainly to identify a subset of
genetic mutations associated with a given drug resis-
tance profile and, secondarily, to use the identified
mutations to predict unknown places in the given drug
resistance profile (marked by ‘?’).
Genotype data
We collected genotype data (genome sequences and
annotations) for the following 100 fully sequenced
strains of S. aureus from the GenBank [22] and PATRIC
databases [23]. Additionally, genotype data for strain
EMRSA-15 were downloaded from the Wellcome Trust
Sanger Institute website. At the time of writing, 31 out
of the 100 S. aureus strains had “completed” sequencing
status. For the remaining strains whose genomes are
still being assembled, contig sequences (covering around
90% of the genomes) and annotations are provided.
We unify the original annotations employing our pre-
viously published method, called CAMBer [24]. Briefly,
CAMBer iteratively extends the protein-coding annota-
tions by homology transfer, until the transitive closure of a
given homology relation is computed. This homology rela-
tion defines the consolidation graph. In this graph, there is
an edge between a pair of genes if there was an accepteble
BLAST hit between them.
Then, we determine gene families as connected compo-
nents in the consolidation graph. However, we additionally
extend the consolidation graph by edges coming from
BLAST amino-acid queries. More formally, we add an
edge between a pair of genes to the consolidation graph if
the percent of identity (calculated as the number of identi-
ties over the length of the longer gene) of the BLAST hit





100 L ≤ 11
c + 480.L−0.32.(1+e
−L/1000) 11 < L ≤ 450
c + 19.5 L > 450
(1)
Here, c is set to 40.5 and L is the number of aligned
amino acid residues.
Each connected component in the consolidation graph
corresponds to a gene family [24]. We compute multiple
alignments using MUSCLE [26] for all these gene families.
Then, we consider two kinds of genetic variations:
• gene gain/loss,
• amino acid point mutations.
Intuitively, we represent the considered genetic varia-
tions as 0 - 1 vectors, indexed by strains, where 0
denotes the reference state and 1 denotes some change.
We call vectors of these genetic variations as gain/loss
profiles and point mutation profiles.
Gene gain/loss profiles are transformed from gene
families which do not span the set S of all considered
strains. For each such gene family, we transform it into
a vector representation g : S → {′G′,′ L′} as follows: for
a given strain i, we define g(i) = ‘G’ if the gene family
contains at least one gene in that gene family for strain
i; otherwise we set g(i) = ‘L’.
Similarly, point mutation profiles are transformed from
columns in multiple alignments computed for gene
families with elements present in at least |S| − 1 strains.
We take into account only columns which contain at
least two different characters (ignoring ‘?’). For each such
column (in the multiple alignment), we transform it into
a vector representation m : S → ∑AA ∪ {′−′,′ ?′} as fol-
lows: for a given strain i, we set m(i) = ‘x’ if the character
‘x’ is present (one of 20 amino-acids or ‘-’) in the row cor-
responding to strain i; and set m(i) = ‘?’ if strain i is not
present in the aligned gene family.
Phylogenetic tree of the strains
We compute the phylogenetic tree of the input strains
using a consensus method with majority rule implemen-
ted in the PHYLIP package [27]. We apply the consen-
sus method to trees constructed for all gene families
with exactly one element in each strain. The trees are
constructed using the maximum likelihood approach
implemented in the PHYLIP package [27].
Phenotype data (drug susceptibility)
Drug susceptibility data were collected from the follow-
ing sources: (i) publications issued together with the
fully sequenced genomes: USA300_TCH1516 and
USA300_TCH959 [28], MRSA252 and MSSA476 [29],
04-02981 [30], T0131 [31], ST398 [32], COL [33],
JKD6008 [34], 16 K [35], TW20 [36], Newman [37],
RN4220 [38], O46 and O11 [39], RF122 [40], Mu3 [41],
MRSA252 [29], CF-Marseille [42], N315 and Mu50 [43],
MW2 [44], MSHR1132 [45], ECT-R_2 [46], JH1 and
JH9 [17], ED98 [47], JKD6159 [48], LGA251 [49],
ED133 [50]; (ii) NARSA project http://www.narsa.net;
(iii) email exchange with the authors of publications
related to strains ST398 and TW20; and (iv) other pub-
lications found by searching of related literature
[21,23,33,37,51-98]. The complete collected phenotype
data are available in the supplementary table (additional
file 1).
We represent the collected information as a set of
drug resistance profiles, defined for each drug separately.
Essential mutations
For a given drug resistance vector v we introduce a
function rv which describes the reference state of a
given point mutation or gene gain/loss profile p. We
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define it as the most often-occurring state in drug-sus-










p (i) = x
]
(2)
Here, and in all the following equations, square brack-
ets are used for Iverson’s notation.
In the current implementation, in the case when there
is a multiple number of states present in the same maxi-
mal number of strains, the function rv returns the first
state in the lexicographical order. Note that this is just a
technical assumption, since such mutations will not be
considered as associated with drug resistance.
We say that a point mutation m is present in a strain i
if m(i) ∉ {rv(m),’?’}; otherwise we say that the point
mutation m is absent in strain i.
Then, we distinguish two categories of gene gain/loss
and point mutation profiles depending on how they corre-
spond to a given drug resistance profile. We categorize a
given mutation profile m as:
• essential mutation, when m is absent in all drug-
susceptible strains,
• conflict mutation, when m is present in at least one
drug-susceptible strain.
Further, we distinguish neutral mutations as a subclass
of essential mutations, these are essential mutations that
are not present in any of drug-resistant strains.
Analogously, we transfer the above introduced concepts
to gene/loss profiles, defining essential, neutral and conflict
gain/loss profiles.
Support
We aim to identify genetic variations which are likely to be
associated with drug resistance. Intuitively, such mutations
or gained genes should often be present in drug-resistant
strains and rarely in drug-susceptible strains. To reflect
this intuition we assign a score, which we call a support, to
all point mutation and gene gain/loss profiles. For a given
point mutation or gene gain/loss profile p and drug resis-
tance profile v, the support (sv) is defined as the number of
drug-resistant strains with the mutation present (or gene
gained) minus the number of drug-susceptible strains with




















Here, av is a weight which we use to punish muta-
tions for their presence in drug-susceptible strains. It is
defined as the proportion of the number of drug-resis-
tant to the number of drug-susceptible strains, so that
occurrences of a mutation are given equal emphasis in







Although the support is a simple and intuitive score, it
does not incorporate any phylogenetic information. For
example, let us assume there are two point mutations
with the same support 3, where the first mutation covers
only drug-resistant strains within one subtree of the
phylogenetic tree, whereas the second mutation covers
the same number of strains but spread throughout the
whole tree. The first mutation is likely to be associated
with the phylogeny, driven by some environmental
changes. This suggests that the second mutation should
have a greater score as it has to be acquired a few times
independently during the evolution process.
We propose weighted support as a score to account for
the above situation. For a given phylogenetic tree T and
gene gain/loss or point mutation profile p, weighted sup-















where wTi are weights assigned to each cell in a given
drug resistance profile.
In all our experiments we assign weights in the follow-
ing way: all drug-susceptible strains are assigned weight




, where n is the number of drug-
resistant strains in the subtree (containing strain i)
determined by its highest parental node, such that the
subtree does not contain any drug-susceptible strain in
its leaves. All strains without drug resistance informa-
tion are assigned weights 0.
Note that the support score can also be expressed as
weighted support, where wi are assigned as -av, 1, 0 for
drug-susceptible, drug-resistant and strains without drug
resistance information, respectively.
Figure 1 illustrates the concept of support and weight-
support.
In order to make the support scores more comparable
between drugs, we introduce normalized versions of the
scores, normalized support and normalized weighted sup-
port which denote the respective support value divided the
maximal possible support or weighted support, respectively.
Odds ratio
For a given drug resistance profile v and mutation p, we
calculate odds ratio using the formula:
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max (1,nR0) · max (1,nS1) (6)
Here, nR1, nS0, nR0 and nS1 denote the number of
drug-resistant strains with mutation p, drug-susceptible
strains without mutation p, drug-resistant strains with-
out mutation p and drug-susceptible strains with muta-
tion p, respectively.
The same formula is used to calculate odds ratio for
gene gain/loss profiles.
Statistical significance
In order to assess statistical significance of the associa-
tions we calculate their p-value.
More precisely, for a given drug resistance profile v,
let X be the random variable giving support of a random
mutation. Then, for a given observed mutation with sup-
port = c, its p-value is defined by the following formula:
P (X ≥ c) =
|S|∑
n=1
P (X ≥ c|N = n) · P (N = n) (7)
Here, N is a random variable which denotes the num-
ber of mutated strains in a random mutation. For each
n the probability ℙ(N = n) of observing a mutation pre-
sent in n strains is estimated (as the number of muta-
tions present in n strains to the total number of
considered mutations) from the data for point mutation
and gene gain/loss profiles separately. The details follow.
Assume that weights, for a given drug resistance profile
v, take k different values: l1, l2, ..., lk. For 1 ≤ j ≤ k, let mj
be the number of strains which take value lj. Clearly we
have m1 + m2 + ... + mk = |S|. Then, the probability ℙ(X
≥ c|N = n) (from the equation 7) is given by the for-
mula:
∑
0 ≤ n1 ≤ m1
0 ≤ n2 ≤ m2
· · ·
0 ≤ nk ≤ mk
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Figure 1 Support and weighted support. A schematic example of classification of genetic variation profiles and computation of their supports.
Point mutations 1 and 4 are essential, mutation 2 is conflict and mutation 3 is neutral. Light blue circles mark nodes which appear in the
definition of weighted support. These are nodes the highest parental nodes (for the leaf nodes corresponding to drug-resistant strains), that their
subtrees do not contain any drug-susceptible strains in leaves. The scores (a) support and (b) weighted support are assigned to these mutations.
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Here we describe our algorithm for calculating the p-
value. It should be clear that the problem reduces to
computing P (X ≥ c|N = n) =
tc (n)(|S|
n
) for each 0 ≤ n ≤ |S|,
where tc(n) denotes the number of ways for distributing
n ones over |S| strains, such that the corresponding sum





the total number of possible ways for distributing n ones
over |S| strains. Thus, the problem reduces to calculating
tc(n) for each 0 ≤ n ≤ |S|. Additionally, without any loss
of generality, we may assume that the weight levels are
strictly decreasing: l1 >l2 > ... >lk, where lk < 0 and lk-1 ≥ 0.
The algorithm iteratively generates partial combina-
tions (without nk) starting from the partial combination
(n1 = m1, ..., nk - 1 = mk - 1) in the following manner: if j
is the highest index of the non-zero ni in the current
partial combination, the next partial combination will be
(n1, ..., nj - 1, nj + 1 = mj + 1, ..., nk - 1 = mk - 1). The
algorithms terminates generating partial combinations
when two following partial combinations have their cor-
responding sum of weights below the level of c. At each
step of the algorithm, all possible full combinations
(n1, ... nk - 1, nk) are generated from the current partial
combination (n1, ... nk - 1). If for the full combination its
corresponding sum of weights is greater or equal
c
(∑k
i=1 ni · li ≥ c
)





, where n = n1 + ... + nk. As the outcome, we
obtain tc(n) and, thus, also ℙ(X ≥ c|N = n) for each n.
The last step is to calculate formula 7 using these cal-
culated probabilities.
Note that, since support is a special case of weighted
support, the same formula and algorithm can be used to
compute its corresponding p-values.
Results and discussion
We verify the usability of our approach by trying to re-
identify the known drug resistance determinants. In this
experiment, we compare our proposed scoring methods
–support and weighted support –to odds ratio, which is a
popular measure used in genome-wide association studies.
Table 1 shows rankings of the gene gain/loss profiles cor-
responding to genes which are known drug resistance
determinants. The experiment suggests that weighted sup-
port identifies putative associations better than support
and odds ratio, both of which do not incorporate addi-
tional information about phylogeny.
This experiment also reveals that the amount of the
collected drug resistance information is not sufficient to
correctly identify drug resistance associated genes. How-
ever, the high consistency of drug resistance profiles
corresponding to the collected information and the pre-
sence of drug resistance determinants (summing over
drugs, there are 117 drug resistant strains, where only 4
of them do not have any known drug resistance deter-
minants; and there are 112 drug-susceptible strains,
where only 8 of them have at least one drug resistance
determinant) suggests that we can use the determinants
to predict drug resistance in the strains without drug
resistance information available. It is perhaps question-
able to predict drug resistance in those strains for which
the whole-genome sequence is not determined yet. So
we do prediction only for those strains with completed
sequencing or at least information on their plasmids
Table 1 Rankings of known drug resistance determining genes
Rankings before prediction Rankings after prediction
gene id. drug name S WS OR S WS OR
tet Tetracycline 54.5 2.5 43.7 1.5 1.5 1.5
tetM Tetracycline 14.5 11.5 7.5 4 4 4
mecA Methicillin 1 1 1 1 1 1
mecA Oxacillin 3 4 2 1 2 1
ermA1 Clindamycin 5.5 5.5 5.5 1 1 1
ermC Clindamycin 907 471 907 414.5 11 191.5
ermA1 Erythromycin 3 3 4 1 1 1
ermC Erythromycin 1527 3994.5 1006.5 413.5 28 214.5
aacA-aphD Gentamicin 72 34 34 1 1 1
blaZ Penicillin 163 66 223 1.5 1 2.5
mecA Penicillin 163 8 223 11 5 52
Average ranking (excluding ermC): 53.27 15.05 60.411 2.55 1.94 7.22
Rankings of the known drug resistance determinants obtained by employing three different methods to score gene gain/loss profiles: support (S), weighted
support (WS) and odds ratio (OR). Since some of the gene gain/loss profiles are assigned with the same score, we calculate their rankings as the arithmetic mean
of positions of the profiles with the same score on the list sorted according to the scores; thus some of the rankings are not round numbers. The rankings were
computed before and after prediction of drug resistance, which is based on the presence of the drug resistance determinants. We excluded the gene ermC from
the calculations of the rankings since none of the methods were able to pull it out into the top 100 before prediction.
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(which often carry the drug resistance determinants).
Nevertheless, we predict drug resistance also for those
strains that are not yet fully sequenced, provided the
presence of drug resistance determining genes has been
confirmed for them. Moreover, we predict drug resis-
tance to rifampicin and ciprofloxacin for all 100 strains,
as the drug resistance for rifampicin and ciprofloxacin is
determined by point mutations in genes rpoB, gyrA and
grlA (synonymous name to parC), which are sequenced
in all strains. More precisely, we predicted as rifampi-
cin-resistant all strains with any mutation present in the
rifampicin resistance determining region (RRDR). We
defined the RRDR as the amino-acid range from 463 to
530 in the rpoB gene sequence (according to [94]). Ana-
logously, we predicted as ciprofloxacin-resistant all
strains with any point mutation in the quinolone resis-
tance determining region (QRDR). We defined QRDR as
the amino-acid ranges from position 68 to 107 and from
position 64 to 103 in the grlA and parC gene sequences,
respectively (according to [65]). Figure 2 shows the
complete information about drug susceptibility after
prediction.
Then, we applied our approach to the dataset supple-
mented by the predicted information about drug suscept-
ibility for the following drugs: tetracycline, b-lactames
(penicillin, oxacillin, methicillin), erythromycin, gentami-
cin, vancomycin, ciprofloxacin and rifampicin.
We discuss in the subsections below the results of our
approach applied separately to the following drugs: tetra-
cycline, b-lactames (penicillin, methicillin), erythromycin,
gentamicin, vancomycin, ciprofloxacin. We do not dis-
cuss here results for oxacillin and clindamycin, since they
have very similar drug resistance profiles to methicillin
and erythromycin, respectively. All other drugs were
excluded from the analysis due to the low number of
strains with available drug resistance information on
these drugs.
Tables 2 and 3 present the top-scored gene gain/loss, and
point mutation profiles for the dis-cussed drugs, respec-
tively. The genes presented in the tables were selected
according to the following procedure: for each drug we
construct a function, which gives for each gene (listed in
descending order with respect to normalized weighted sup-
port) the minus logarithm of p-value (-log(p-value)) of this
score. Then, we report genes which correspond to the por-
tion of the graph of this function before it gets flattened.
Complete results for all the drugs are provided in supple-
mentary Excel tables (additional files 3 and 4).
Tetracycline
Tetracycline acts by binding to the 30S ribosomal subu-
nit (rpsS, 16S rRNA are its direct targets), preventing
binding of tRNA to the mRNA-ribosome complex, and
thus inhibiting protein synthesis [7].
The most common drug resistance mechanism to tet-
racycline in S. aureus is mediated by ribosome protec-
tion proteins (RPPs) such as tet and tetM, which bind to
the ribosome complex, thus preventing the binding of
tetracycline [99,100].
Proteins tet and tetM mediating the mechanism cover
all drug-resistant strains except MW2. This may be
caused by errors in the drug susceptibility tests, errors
in sequencing, or by some other not yet known drug
resistance mechanism. The inconsistent information
about strain MW2’s tetracyline susceptibility (see sup-
porting Table 1) and the lack of identified drug resis-
tance determinants suggest that the strain is possibly
drug susceptible. In our experiment we initially assumed
that the tetracycline resistance information is not avail-
able for strain MW2.
Our method shows that, besides tet and tetM, there
are a few more genes that have highly scored gene gain/
loss profiles. Especially interesting are the following
genes which are not gained by any of the drug suscepti-
ble strains: repC, pre, thiI, int, clfB (see Table 2). There
are studies reporting the significance of these clfB and
repC genes in drug resistance [101,102]. Interestingly,
the gene repC seems to co-evolve with tet (correlated
gene gain/loss profiles).
Applying our method to point mutations we have
identified two highly scored (and essential) point muta-
tions in ribosomal complex proteins: K101R in rpsL and
K57M in rpsJ. According to our knowledge, this is the
first report on the significance of the point mutations
for drug resistance in S. aureus. However, we found a
study associating mutations in rpsJ with tetracycline
resistance in another bacteria Neisseria gonorrhoeae
[103].
Beta-lactams
Beta-lactams are a broad class of antibiotics, which pos-
sess (by definition) the b-lactam ring in their structure.
The ring is capable of binding transpeptidase proteins
(also known as Penicillin Binding Proteins – PBPs) [7],
which are important to synthesis of the peptidoglycan
layer of bacterial cell wall. PBPs with attached drug
molecules are no longer able to synthesize peptidogly-
can, leading to bacterial death [104]. In our case study
we consider three b-lactam antibiotics: penicillin, oxacil-
lin and methicillin. However, since the drug resistance
profile and drug resistance mechanisms for oxacillin and
methicillin are very similar we discuss results only for
methicillin.
There are two common b-lactames resistance
mechanisms in S. aureus [104,105]. The first one is
mediated by b-lactamase enzymes, which bind drug
molecules and break the b-lactam ring, thus deactivating
the drug molecules. This mechanism is effective against
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penicillin (which is b-lactamase sensitive) and not effec-
tive against methicillin and oxacillin (which are b-lacta-
mase resistant) [106]. The second b-lactam resistance
mechanism is mediated by proteins which are capable of
functionally substituting for PBPs, but have much smal-
ler affinity to b-lactam molecules. This mechanism is
effective against penicillin, methicillin and oxacillin.
Penicillin
In our dataset all strains resistant to penicillin possess
proteins responsible for one of the two mechanisms.
More precisely, there are 69 drug-resistant strains (with
available drug resistance information), which possess
BlaZ – the standard b-lactamase protein (note that its


































































H19 ? r ? ? ? ? ? ? s s 
D139 ? ? ? ? ? ? ? ? s s 
M013 ? r r r s s s s s s 
RF122 ? s s s s s s s s s 
JKD6159 S r R r S S S s S S 
21235 ? ? ? ? ? ? ? ? s s 
ED133 ? s s s s s s s s s 
LGA251 ? R R R S S S S S S 
21269 ? r ? ? ? ? ? ? s s 
O11 ? ? ? ? ? ? ? ? s s 
O46 ? ? ? ? ? ? ? ? s s 
ST398 S R R R R S S s R S 
TCH60 ? r R r s s s s s s 
WBG10049 ? r R r ? ? ? ? s s 
C427 ? r ? ? ? ? ? ? s s 
A01793497 ? r R r ? ? ? ? s s 
WW270397 ? r R r ? ? ? ? s s 
CGS00 ? r ? ? ? r r ? s s 
Btn1260 ? r S ? ? ? ? ? s s 
MRSA252 S R R R S R R S R S 
EMRSA16 ? r R r ? r r ? r s 
MN8 S R S S S S S S S s 
C160 ? r ? ? ? ? ? ? s s 
21195 ? ? ? ? ? ? ? ? s s 
552053 ? r S ? ? ? ? ? s s 
M1015 ? r S ? ? ? ? ? s s 
M809 ? r S ? ? ? ? ? s s 
C101 ? r S ? r ? ? ? s s 
E1410 ? R S ? S ? ? ? s s 
M876 ? r S ? ? ? ? ? s s 
M899 ? r S ? r ? ? ? s s 
58-424 ? R ? ? R R r ? s s 
65-1322 ? R ? ? R R r ? s s 
68-397 ? R ? ? R R r ? s s 
MSHR1132 ? r r R s s s s s s 
21200 ? r ? ? ? ? ? ? s s 
A9635 S r ? ? ? ? ? ? s s 
EMRSA15 ? r r r s r r s r s 
21310 ? r ? ? ? ? ? r s s 
MR1 ? r R r r ? ? ? s s 
ED98 ? s s s r s s s r s 
A9299 S ? ? ? ? ? ? ? s s 
21201 ? r ? ? ? ? ? ? s s 
A8117 S ? ? ? r ? ? ? s s 
A8115 S ? ? ? r ? ? ? s s 
CF-Marseille ? r R r R R r S r s 
Mu50-omega S r R R R R R R R r 
Mu50 R R R R R R R R R R 
Mu3 S R R R R R R R R S 



































































21318 ? r ? ? ? ? ? ? s s 
ECT-R_2 ? r S s s R R s r s 
A9763 S r r r ? r r ? r s 
A5937 ? r r r ? r r ? r s 
A6224 S r r r ? r r ? r r 
04-02981 S R R R S R R S R s 
A6300 ? r r r ? r r ? r r 
A10102 S r r r ? r r ? r s 
A8796 S r r r ? r r ? r s 
21172 ? r ? ? ? r r ? r r 
A8819 S r r r ? r r ? r s 
CGS03 ? r r r ? r r ? r s 
JH9 R r R S S R R r r R 
JH1 S r R S S R R r r S 
A9781 S r r r ? r r ? r s 
A9719 S r r r ? r r ? r s 
21305 ? r ? ? r ? ? ? s s 
21193 ? r ? ? ? ? ? ? s s 
USA300_TCH959 S R S S S S S S S S 
11819-97 ? r R r s s s s s s 
NCTC_8325 S S S S S S S S S S 
21189 ? ? ? ? ? ? ? ? s s 
VC40 R s s s s r r s s s 
RN4220 S S S S S S S S S S 
A5948 S r r r ? r r ? s s 
132 ? r r r ? ? ? ? r s 
D30 ? ? ? ? ? ? ? ? s s 
MRSA131 S r R r ? ? ? S S S 
MRSA177 S r R r r ? ? S S S 
CGS01 ? r r r ? ? ? ? s s 
USA300_TCH1516 S R R R S R S S S S 
A9754 S r r r r ? ? ? r r 
USA300_FPR3757 S R R R R R R s R S 
930918-3 ? r ? ? ? r r ? s s 
A9765 S r r r r r r r r r 
COL S R R R R S S S S s 
Newman S S S S S s s s S s 
TW20 S R R r R R r R R S 
T0131 ? r R r r r r s r r 
16K ? r r r r s s r r R 
JKD6009 S r R R R r r R R s 
JKD6008 R r R R R r r R R s 
ATCC_BAA-39 ? r r r r r r r r s 
ATCC_51811 ? r ? ? ? ? ? ? s s 
TCH70 ? r r r ? r r ? s s 
MW2 S R R R R S S S S s 
MSSA476 S R S S S S S S S S 
21259 ? ? ? ? r ? ? ? s s 
TCH130 ? r ? ? ? r r ? s s 
21266 ? r ? ? ? ? ? ? s s 
 
Figure 2 The collected dataset of phenotypes with predictions. The collected dataset of phenotypes put together with results of our drug
resistance predictions based on the presence of known drug resistance determinants. Due to the high number of strains the table is split into
two panels. Columns represent drugs, rows represent S. aureus strains included in the study in the order corresponding to the reconstructed
phylogenetic tree of strains. Green, yellow and red cell colors represent susceptible, intermediate resistant and resistant phenotypes, respectively.
Analogously, light green and light red cell colors represent predicted susceptible and resistant phenotypes, respectively. White cell color
represents unknown (not determined by experiments or prediction) drug resistance phenotypes.
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Table 2 The top scored gene gain/loss profiles
Gene identifier NS NWS OR p-value Gene functional annotation
Penicillin (NWS-threshold: 0.58)
SAR1831(blaZ) 0.84 0.81 37.15 1.15e-06 beta-lactamase
SAR1829(blaI) 0.84 0.74 37.15 5.24e-06 transcriptional repressor
SAR1830(blaR1) 0.82 0.73 31.27 7.09e-06 beta-lactamase regulatory protein blar1
SAR0056 0.63 0.71 12.13 1.03e-05 conserved hypothetical protein
SAR0039(mecA) 0.61 0.70 10.94 1.28e-05 penicillin-binding protein pbp2a, methicillin resistance determinant mecA, transpeptidase
SAR0060(ccrA) 0.61 0.63 10.94 4.40e-05 resolvase, n-terminal domain protein
SAR0061(yycG) 0.61 0.63 10.94 4.40e-05 putative membrane protein
NWMN 0025 0.57 0.63 9.40 4.41e-05 conserved domain protein
SAR0037(ugpQ) 0.60 0.63 10.39 5.08e-05 glycerophosphoryldiester phosphodiesterase
SAR0038(maoC) 0.60 0.63 10.39 5.08e-05 dehydratase
SAR0057 0.57 0.59 9.40 9.78e-05 conserved hypothetical protein
Methicillin (NWS-threshold: 0.68)
SAR0039(mecA) 1.00 1.00 950.00 4.48e-20 penicillin-binding protein pbp2a, methicillin resistance determinant mecA, transpeptidase
SAR0037(ugpQ) 0.98 0.94 931.00 6.77e-15 glycerophosphoryldiester phosphodiesterase
SAR0038(maoC) 0.98 0.94 931.00 6.77e-15 dehydratase
SAR0056 0.95 0.85 900.00 7.55e-12 conserved hypothetical protein
SAR0036 0.64 0.80 33.78 5.77e-11 putative membrane protein
SAR0057 0.85 0.75 162.00 6.47e-10 conserved hypothetical protein
SAR0060(ccrA) 0.91 0.73 432.00 1.40e-09 resolvase, n-terminal domain protein
SAR0061(yycG) 0.91 0.73 432.00 1.40e-09 putative membrane protein
MW0028(ebpS) 0.54 0.71 22.30 2.76e-09 hmg-coa synthase
Tetracycline (NWS-threshold: 0.32)
SAAV_b3(repC) 0.54 0.64 27.69 5.70e-08 plasmid replication protein
SATW20_00660(tet) 0.54 0.64 27.69 5.70e-08 tetracycline resistance protein
SATW20_00670(pre) 0.50 0.50 24.00 3.51e-06 plasmid recombination enzyme type 3
SATW20_04620(tetM) 0.46 0.37 20.80 7.54e-05 tetracycline resistance protein tetM
SATW20_08990(virE) 0.42 0.37 19.93 7.67e-05 pathogenicity island protein
SATW20_09000 0.42 0.37 19.93 7.67e-05 pathogenicity island protein
SATW20_09010(lipA) 0.42 0.37 19.93 7.67e-05 putative protein in superantigen-encoding pathogenicity islands
SATW20_04610(thiI) 0.43 0.35 18.00 1.32e-04 putative transcriptional regulator
MW0745(int) 0.25 0.32 8.00 2.28e-04 site-specific recombinase, phage integrase family
MW0747 0.25 0.32 8.00 2.28e-04 DNA-binding helix-turn-helix protein
Erythromycin (NWS-threshold: 0.27)
SAR0050(ermA1) 0.80 0.58 76.00 1.36e-06 rRNA adenine n-6-methyltransferase
CGSSa03 12660 0.47 0.44 17.19 2.98e-05 conserved hypothetical protein
SAR0054(tnpA1) 0.75 0.39 72.00 8.12e-05 transposase for transposon
SAR1734 0.75 0.39 72.00 8.12e-05 methylase
SAR1736(spc2) 0.75 0.39 72.00 8.12e-05 spectinomycin 9-o-adenylyltransferase
SaurJH9_1711(radC) 0.72 0.38 62.00 8.83e-05 predicted protein
SAUSA300_pUSA030006 0.20 0.35 4.75 1.65e-04 replication and maintenance protein
SAR1737(tnpC2) 0.72 0.34 62.00 1.89e-04 Unknown
SAR1529 0.33 0.33 9.15 2.43e-04 conserved hypothetical protein
SATW20_04860(recF_1) 0.23 0.30 5.52 3.67e-04 recombinational DNA repair ATPase
SAR1738(tnpB2) 0.70 0.29 54.00 4.39e-04 transposase B from transposon Tn554












bifunctional acetyltransferase/phosphotransferase GNAT family acetyltransferase
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Table 2 The top scored gene gain/loss profiles (Continued)
Ciprooxacin (NWS-threshold: 0.4)
SATW20_04610(thiI) 0.35 0.45 36.00 1.33e-07 putative transcriptional regulator
SATW20_04650(cap8J) 0.32 0.40 31.57 8.25e-07 lipoprotein
SATW20_04670(capL) 0.32 0.40 31.57 8.25e-07 putative ATP/GTP-binding protein
SATW20_04780 0.32 0.40 31.57 8.25e-07 conjugation related protein
SATW20_04800 0.32 0.40 31.57 8.25e-07 replication initiation factor
SATW20_04810 0.32 0.40 31.57 8.25e-07 DNA segregation ATPase FtsK/SpoIIIE
SATW20_04830 0.32 0.40 31.57 8.25e-07 conjugative transposon protein
Summarizing information for the top scored gene gain/loss profiles. The consequent columns refer to: gene identifier of the corresponding gene family;
normalized support (NS); normalized weighted support (NWS); odds ratio (OR); p-value and the gene functional annotation. Thresholds for weighted support are
provided in brackets for each drug. Colored gene gain/loss profiles are provided in the supplementary the (additional file 3). Complete results for all the drugs
are provided in the supplementary Excel table (additional files 2).
Table 3 The top scored point mutation profiles, only for essential mutations
Gene identifier desc. NS NWS OR p-value Gene functional annotation
Penicillin (NWS-threshold: 0.4)
SAR0023(sasH) G723D 0.55 0.63 8.51 1.87e-05 virulence-associated cell-wall-anchored protein; 5’-nucleotidase
SAR0023(sasH) T725A 0.54 0.62 8.11 2.23e-05 virulence-associated cell-wall-anchored protein; 5’-nucleotidase
SAR0304 V295I 0.39 0.49 4.48 3.25e-04 acid phosphatase
SAR2791 V182M 0.46 0.46 6.05 5.41e-04 transcriptional regulator, Xre family
SAR2700 N493KD 0.52 0.45 7.72 6.16e-04 ABC transporter permease protein
SAR0233(hmp) Q333K 0.44 0.44 5.48 7.21e-04 avohemoprotein (nitric oxide dioxygenase)
SAR0318(sbnA) N25HK 0.44 0.43 5.48 8.36e-04 alpha/beta family hydrolase
SAR2664 V282AT 0.44 0.43 5.48 8.36e-04 probable monooxygenase
SAR2779 S48G 0.44 0.43 5.48 8.36e-04 n-hydroxyarylamine o-acetyltransferase
SAR0318(sbnA) T138IM 0.43 0.43 5.21 8.36e-04 alpha/beta family hydrolase
SAR0318(sbnA) T139AQ 0.43 0.43 5.21 8.36e-04 alpha/beta family hydrolase
SAR0023(sasH) A749TG 0.41 0.43 4.96 8.44e-04 virulence-associated cell-wall-anchored protein; 5’-nucleotidase
SAR0318(sbnA) R130CG 0.41 0.43 4.96 8.72e-04 alpha/beta family hydrolase
SAR0322(folC) H201YQE 0.41 0.43 4.96 8.72e-04 macro domain, possibly adp-ribose binding module
SAR0233(hmp) K323ET 0.40 0.42 4.71 9.08e-04 avohemoprotein (hemoglobin-like protein)
SAR2750(icaC) I21V 0.40 0.42 4.71 9.46e-04 polysaccharide intercellular adhesin (PIA) biosynthesis protein
SAR0233(hmp) S309RN 0.39 0.42 4.48 9.46e-04 avohemoprotein (hemoglobin-like protein)
Methicillin (NWS-threshold: 0.25)
SAR0198(oppF) T287IK 0.10 0.29 2.11 1.41e-04 putative glutathione transporter, ATP-binding component
SAR0420 I72F 0.10 0.29 2.11 1.41e-04 membrane protein
SAR2508(sbi) S219AT 0.10 0.29 2.11 1.41e-04 IgG-binding protein Sbi
SAR2508(sbi) N222QK 0.10 0.29 2.11 1.41e-04 IgG-binding protein Sbi
SAR2508(sbi) K224SDN 0.10 0.29 2.11 1.41e-04 IgG-binding protein Sbi
Tetracycline (NWS-threshold: 0.2)
SAR1840 D291YS 0.18 0.23 5.22 7.09e-04 NAD(FAD)-utilizing dehydrogenases
SAR2336(rpsJ) K57M 0.29 0.23 9.60 7.32e-04 SSU ribosomal protein S10P (S20E)
SAR0550(rpsL) K113R 0.36 0.20 13.33 1.14e-03 SSU ribosomal protein S12P (S23E)
Erythromycin (NWS-threshold: 0.2)
SAR0576 A68EV 0.07 0.21 1.54 8.89e-04 phosphoglycolate phosphatase
Gentamicin (NWS-threshold: 0.21)
SAR1840 L289IW 0.33 0.29 15.00 1.43e-03 NAD(FAD)-utilizing dehydrogenases
SAR1840 D291YS 0.33 0.29 15.00 1.43e-03 NAD(FAD)-utilizing dehydrogenases
SAR1840 H327RF 0.33 0.29 15.00 1.43e-03 NAD(FAD)-utilizing dehydrogenases
SAR1167(ylmH) K215N 0.25 0.29 10.00 1.43e-03 RNA-binding S4 domain-containing protein
SAR1167(ylmH) R216V 0.25 0.29 10.00 1.43e-03 RNA-binding S4 domain-containing protein
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All the remaining penicillin-resistant strains have mecA,
which is an altered PBP. Table 2 provides information
about the top-scored gene gain/loss profiles.
Applying our method we have also identified the
uncategorized putative protein, SAR0056, as putatively
associated with penicillin resistance (see Table 2). We
suggest to examine further the role of that gene in
b-lactams resistance.
Methicillin
Applying our approach to gene gain/loss profiles we
identified (beside mecA) genes ugpQ and maoC. The
correlation of gene profiles to the profile of mecA and
their close proximity on the genomes suggests that
these genes co-evolve (see Figure 3 for more details).
This co-evolution may reflect some important role
played by these genes in methicillin resistance. This
calls for further study of the role of these two genes in
methicillin resistance.
We have also identified a few point mutations that are
putatively associated with methicillin resistance. Inter-
estingly, two of the mutations in the top 10 essential
mutations according to weighted support (I72F in
SAR0420 and E208QKD in SAR0436) are present in cell
membrane proteins. This suggests some compensatory
mechanism to the presence of mecA.
Ciprofloxacin
Ciprofloxacin belongs to a broad class of antibiotics,
called fluoroquinolones, which are functional against
bacteria by binding DNA gyrase subunit A (encoded by
gyrA) and DNA topoisomerase 4 subunit A (encoded by
parC), which are enzymes necessary to separate bacterial
DNA, thereby inhibiting cell division [7]. The most
common ciprofloxacin resistance mechanism is
mediated by point mutations in the drug targets, parC
and gyrA.
Applying our approach we identified (by highest sup-
port) two point mutations in ciprofloxacin target genes
– S80 FY in parC and S90 AL in gyrA – which are
located in QRDR and known to be responsible for the
first mechanism of ciprofloxacin resistance [65]. The
presence of these mutations is correlated with the cipro-
floxacin resistance profile for strains with available drug
resistance information. However, they differ for two
strains ED98 and 16 K (only the mutation in parC is
present). This may suggest intermediate drug resistance
level for these strains. Unfortunately ciprofloxacin resis-
tance information is not available for these strains.
Erythromycin
Erythromycin acts by binding the 23S rRNA molecule
(in the 50S subunit) of the bacterial ribosome complex,
leading to inhibition of protein synthesis [7].
There are three known erythromycin resistance
mechanisms [107]. First – the most common mechanism
– is by methylation (addition of two residues to the
domain V of 23S rRNA) of the 23S rRNA molecule, which
prevents the ribosome from binding with erythromycin.
This methylation is mediated by enzymes from the erm
gene family, the most common are ermA and ermC. The
second mechanism is mediated by the presence of macro-
lide efflux pumps (encoded by msrA and msrB). The third
mechanism is the inactivation of drug molecules by spe-
cialized enzymes such as EreA or EreB [107].
We found that none of the strains in our case study
possess genes EreA or EreB. Genes encoding efflux
Table 3 The top scored point mutation profiles, only for essential mutations (Continued)
SAR1167(ylmH) V217L 0.25 0.29 10.00 1.43e-03 RNA-binding S4 domain-containing protein
SAR0547(rpoB) D471YG 0.17 0.21 6.00 4.61e-03 DNA-directed RNA polymerase beta subunit
SAR1833(trmB) T54IK 0.17 0.21 6.00 4.61e-03 tRNA (guanine46-n7-)-methyltransferase
Ciprooxacin (NWS-threshold: 0.12)
SAR1367(grlA) S80YF 1.00 1.00 2244.00 6.03e-30 topoisomerase IV subunit a
SAR0006(gyrA) S90AL 0.94 0.88 1056.00 1.92e-18 DNA gyrase subunit a
SAR2449(lytT) V45I 0.21 0.20 17.11 2.06e-04 transcriptional regulator
SAR1840 L289IW 0.12 0.20 8.80 4.56e-04 NAD(FAD)-utilizing dehydrogenases
SAR1793(thiI) A92ET 0.09 0.20 6.39 2.06e-04 thiamine biosynthesis protein thiI
SAR2212(murA2) A102T 0.06 0.20 4.12 2.06e-04 UDP-n-acetylglucosamine 1-carboxyvinyltransferase
SAR1367(grlA) E84KG 0.26 0.15 23.76 9.40e-04 topoisomerase IV subunit a
SAR0235(pstG 1) F401LV 0.09 0.13 6.39 2.21e-03 PTS system, maltose and glucose-specific IIC component
SAR0400(nfrA) R194H 0.09 0.13 6.39 2.21e-03 nitroreductase family protein
Summarizing information for the top scored point mutation profiles, only for essential mutations. The conflict mutatations were removed from the table for:
tetracycline, erythromycin and gentamicin (for the rest of drugs there were no conflict mutations above the set thresholds). The consequent columns refer to:
gene identifier of the corresponding gene family; corresponding position in the multiple alignment and changed amino acids; normalized support (NS);
normalized weighted support (NWS); odds ratio (OR); p-value and the gene functional annotation. Thresholds for weighted support are provided in brackets for
each drug. Colored gene gain/loss profiles are provided in the supplementary the (additional file 4). Complete results for all the drugs are provided in the
supplementary Excel table (additional files 5).
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pumps (msrA and msrB) are present also in drug-sus-
ceptible strains (for example, NCTC 8325 and New-
man), which may suggest that the mechanism is inactive
for the considered strains of S. aureus or the enzyme
production rates are too small, which we are not able to
account by our method. Using our approach we identi-
fied (by the highest support) the gene ermA responsible


































































































































































































































































































Figure 3 Genes related to methicillin resistance. Presence and relative genome coordinates of genes related to methicillin resistance (mecA,
mecR1, mecI, ccrA, ccrB, ccrC), put together with the identified genes: ugpQ and maoC. The gene presence profiles are clustered with respect to
the genes order. In this figure we include only these methicillin-resistant strains for which all the genes where located on the main genome and
within the same sequence conting (in order to determine the relative positions).
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Here, there is one erythromycin-susceptible strain,
USA300_TCH959, which harbours the ermA gene. This
may suggest disruption of the drug resistance mechan-
ism in that strain, errors in drug susceptibility testing or
errors in sequencing.
Interestingly, we identified gene SAR1736(spc2) (which
is a known spectinomycin resistance determinant) as
potentially associated with erythromycin resistance. This
suggests that drug resistance to spectinomycin and ery-
thromycin co-evolved, despite these two drugs belonging
to different classes according to the ATC drug classifica-
tion system [106].
Gentamicin
Gentamicin works by inhibition of protein synthesis by
binding the 30S subunit of the ribosome complex [108].
Interestingly, strain USA300-FPR3757 exhibits inter-
mediate drug resistance, which is correlated with the
absence of aacA-aphD gene in its genome sequence.
Since our method requires binary information on drug
susceptibility, we marked this strain as drug susceptible
for experiments.
The most common resistance mechanism responsible
for high levels of Gentamicin resistance is mediated by
the drug-modifying enzyme SaurJH1_2806(aacA-aphD).
Applying our methodology we identified the gene
encoding it as likely to be associated with drug resis-
tance (maximal support). Moreover, we identified also
the gene SaurJH1_2805 as putatively associated with
gentamicin resistance. The close proximity of these two
genes in the genomes and their highly correlated gene
gain/loss profiles suggest co-evolution. We hypothesize
that the gene SaurJH1_2805 plays some role in drug
resistance for gentamicin.
Conclusion
In this work we present a novel approach to associate
genes and mutations with drug resistance phenotypes by
comparative analysis of fully sequenced bacterial strains
(within the same species).
In order to apply our approach we collected genotype
and phenotype data. Genome sequences and annotations
were downloaded for 100 fully sequenced S. aureus
strains. A challenge was to collect drug resistance infor-
mation, which is spread throughout the literature. We
retrieved the data from 71 publications. The collected
dataset is available in the supplementary material (addi-
tional file 1).
In our method we consider two types of genetic differ-
ences as potentially associated with drug resistance:
nonsynonymous point mutations and gene acquisition,
represented by their mutation and gene gain/loss pro-
files, respectively. Then, the approach is based on the
newly introduced concept of support, which is a score
assigned to all mutation and gene gain/loss profiles.
Intuitively, the higher support of a mutation profile, the
better chance of the mutation to be associated with the
drug-resistant phenotype. We also generalize the con-
cept of support into weighted support, which incorpo-
rates phylogenetic information.
Applying our approach, we were able to successfully
re-identify most of the known drug resistance determi-
nants. Here, on average, weighted support outperforms
support and odds ratio.
Moreover, applying our methodology, we identified
some putative novel resistance-associated genes and
mutations. We expect that these associations and drug
resistance predictions will attract the experimental
research community to verify their role in drug resis-
tance mechanisms.
Finally, although the presented approach shows pro-
mise, it has some obvious limitations. Firstly, it is not
clear what threshold for the weighted support is appropri-
ate. Secondly, in this approach we only consider genome
variations, whereas some drug resistance mechanisms
may be related to changes in protein production rates
(such as efflux pumps). Thirdly, the current approach
ignores the role of non-coding RNA in drug resistance
mechanisms. That, would not be detected by our
approach. We plan to address these mentioned problems
in some future work.
Additional material
Additional file 1: Collected phenotype and genotype data. Collected
dataset of phenotypes (results of drug susceptibility tests). Columns
represent drugs, rows represent S. aureus strains included in the study,
put in the order corresponding to the reconstructed phylogenetical tree
of strains. Green, yellow and red color cells represent collected
information: susceptibility, intermediate resistance and resistance of
isolates, respectively.
Additional file 4: Excel table with detailed results for point
mutation profiles. Excel table providing results of our approach applied
to point mutation profiles for ten drugs: penicillin, methicillin, oxacillin,
tetracycline, clindamycin, erythromycin, gentamicin, ciprofloxacin,
rifampicin and vancomycin
Additional file 2: Summary table for the top scored gene gain/loss
profiles (same thresholds as for Table 2 are applied). The columns
refer to: gene identifier of the corresponding gene family; normalized
weighted support (NWS); p-value and the drug resistance profiles put
together with gene gain/loss profiles. Each cell in the gene gain/loss
profiles corresponds to one strain, ordered according to the order in
Figure 2. Cells corresponding to drug-resistant and drug-susceptible
strains are colored red and green, respectively. Strains without drug
resistance information are left white. For each gene gain/loss profile p
and its corresponding row, if a cell in this row corresponds to strain i,
such that rv(p) = p(i), then it is colored blue, otherwise it is colored pink.
Additional file 3: Excel table with detailed results for gene gain/loss
profiles. Excel table providing results of our approach applied to gene
gain/loss profiles for ten drugs: penicillin, methicillin, oxacillin,
tetracycline, clindamycin, erythromycin, gentamicin, ciprofloxacin,
rifampicin and vancomycin.
Additional file 5: Table with point mutation profiles for top scored
mutations profiles. Summary table for the top scored gene point
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mutation profiles (same thresholds as for Table 3 are applied). The
columns refer to: gene identifier of the corresponding gene family;
normalized weighted support (NWS); p-value and the drug resistance
profiles put together with point mutation profiles. Each cell in the point
profiles corresponds to one strain, ordered according to the order in
Figure 2. Cells corresponding to drug-resistant and drug-susceptible
strains are colored red and green, respectively. Strains without drug
resistance information are left white. For each point mutation profile p
and its corresponding row, if a cell in this row corresponds to strain i
(assuming the corresponding gene is present in the strain sequence),
such that rv(p) = p(i), then it is colored blue, otherwise it is colored pink.
Cells corresponding to strains without the corresponding gene are left
white.
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